Degania Silicone Ltd.

Degania Silicone Ltd. specializes in the design and manufacturing of medical-grade silicone products, providing innovative solutions focused on healthcare applications. Their offerings include items for wound care, catheterization, and drug delivery systems. Degania Silicone Ltd.

develops advanced medical devices, specifically focusing on silicone solutions for healthcare providers. Founded in 1984 and headquartered in Israel, the company has engaged in 2 funding rounds. Their most recent funding, amounting to USD 27. 00 mn, was led by Viola Group as of November 2016, raising the total amount raised to USD 27.

00 mn and resulting in a current company valuation of USD 68. 00 mn. Degania Medical specializes in the development and manufacturing of advanced medical devices, primarily focusing on innovative solutions for healthcare providers and patients. The company's core offerings include a range of medical-grade silicone products designed for various applications such as wound care, catheterization, and drug delivery systems.

These products enhance patient comfort and safety while addressing critical healthcare challenges, including infection control. Degania Medical serves a diverse clientele, from hospitals and clinics to home healthcare providers, ensuring their solutions meet professional and end-user requirements. Their products are distributed globally, particularly in North America, Europe, and Asia, where they are utilized by healthcare professionals aiming to enhance patient outcomes. Degania Medical generates revenue through direct-to-business sales and partnerships with healthcare institutions and distributors.

The company's revenue streams include one-time purchases and long-term supply agreements, facilitating ongoing relationships with medical facilities. Flagship products are sold in bulk to healthcare providers who integrate these solutions into patient care. Pricing plans are based on contract agreements, reflecting client purchase scales and service requirements, enabling Degania Medical to maintain stable revenue flow while ensuring accessibility across healthcare environments. Degania Silicone Ltd.

is set to focus on the expansion of its product line, with new medical devices targeting unmet clinical needs planned for release in 2024. Additionally, the company aims to enter new markets, specifically targeting Asia and Latin America by the end of 2025. The recent funding of USD 27. 00 mn will be allocated to research and development of these new products and to support the expansion initiatives.

In November 2016, Q Holding, a portfolio company of 3i, completed the acquisition of Degania Silicone, further positioning the company for growth.